Avalon Pharma’s Net Profit Rises 21% to SAR 80 Million in 2024

Middle East Pharmaceutical Industries (Avalon Pharma) reported a 21% increase in net profit, reaching SAR 80 million by the end of 2024, compared to SAR 66 million in 2023, according to the company’s preliminary financial results for the period ending December 31, 2024.

Operating profit grew 16% to SAR 91 million in 2024, up from SAR 78 million in the previous year. Meanwhile, shareholders’ equity (excluding non-controlling interests) increased by 4% to SAR 78 million, compared to SAR 75 million in 2023.

Earnings per share (EPS) rose to SAR 3.99 in 2024, up from SAR 3.29 in 2023.